A new human prostate carcinoma cell line, 22Rv1

In Vitro Cell Dev Biol Anim. Jul-Aug 1999;35(7):403-9. doi: 10.1007/s11626-999-0115-4.


A cell line has been derived from a human prostatic carcinoma xenograft, CWR22R. This represents one of very few available cell lines representative of this disease. The cell line is derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft. Flow cytometric and cytogenetic analysis showed that this cell line represents one hyper DNA-diploid stem line with two clonal, evolved cytogenetic sublines. The basic karyotype is close to that of the grandparent xenograft, CWR22, and is relatively simple with 50 chromosomes. In nude mice, the line forms tumors with morphology similar to that of the xenografts, and like the parental CWR22 and CWR22R xenografts, this cell line expresses prostate specific antigen. Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis. Growth is stimulated by epidermal growth factor but is not inhibited by transforming growth factor-beta1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Division / drug effects
  • Cell Lineage
  • Dihydrotestosterone / pharmacology
  • Epidermal Growth Factor / pharmacology
  • Flow Cytometry
  • Humans
  • Karyotyping
  • Male
  • Mice
  • Mice, Nude
  • Phenotype
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology*
  • Receptors, Androgen / metabolism
  • Transforming Growth Factor beta / pharmacology
  • Transplantation, Heterologous
  • Tumor Cells, Cultured


  • Receptors, Androgen
  • Transforming Growth Factor beta
  • Dihydrotestosterone
  • Epidermal Growth Factor